RAPT Therapeutics’ stock plunges as FDA halts two clinical trials

RAPT Therapeutics Inc. shares RAPT, +1.68%dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment due to liver failure in a trial participant.The U.S. Food and Drug Administration has verbally notified RAPT that a clinical hold has been placed on two trials of zelnecirnon, one in atopic dermatitis and the other in asthma, the company said in a release Tuesday. RAPT said it expects to receive a f